

Executive Summary

Recent PubMed reviews identify dozens of plant-derived phytochemicals with **in vitro** or animal-model activity against glioblastoma, medulloblastoma and other brain tumors. These compounds (flavonoids, stilbenes, alkaloids, terpenoids, tannins, etc.) act via multifaceted mechanisms – e.g. inducing apoptosis (caspase activation, mitochondrial death signals), arresting the cell cycle (p21/Cyclin inhibition), blocking invasion/metastasis (MMP/EMT suppression), inhibiting angiogenesis (VEGF/VEGFR signaling), modulating autophagy or epigenetics (histone deacetylases, microRNAs), and altering tumor immunity (cytokine/TAM effects). For example, green-tea catechins (EGCG) and curcumin have broad antitumor effects [49†L175-L184] [67†L223-L231], quercetin triggers caspase-mediated apoptosis in GBM cells [54†L1248-L1255] [67†L223-L231], and berberine can kill >90% of malignant brain tumor cells in vitro (91% cell kill at 150 µg/mL, 97% with BCNU) [57†L25-L33]. Notably, many of these act on **overlapping targets** (e.g. NF-κB, PI3K/Akt, p53) and can cross the blood-brain barrier (BBB) to some extent [20†L1-L3] [68†L1-L4], but their **pharmacokinetics and safety in vivo remain poorly characterized**. No combination therapy of these 100 compounds has ever been tested in humans – this is strictly a **preclinical hypothesis**. A rigorous lab program must evaluate synergy, toxicity, PK and BBB penetration before any claim of non-contraindication or clinical use.

In this report we compile a **100-molecule database** of anti-brain-cancer phytochemicals, documenting their plant sources, classes, mechanisms, models, dosing, PK/BBB notes, and safety flags. We outline **4–5 experimental combination formulations** (8–25 compounds each) with complementary mechanisms and minimal predicted interactions, complete with proposed in vitro/in vivo dosing and readouts. A down-selection algorithm (100→20→10→5) integrating multi-objective optimization (target coverage, PK, safety) and iterative screening (single-agent potency, pairwise synergy, ADMET gating) is described. Finally, we propose an **experimental workflow** (with mermaid flowchart) and key assays (cell viability, apoptosis, invasion, angiogenesis, BBB-PAMPA, pharmacokinetics, orthotopic rodent models, survival/cognition) for a lab-based preclinical program. Throughout, we stress the **preclinical exploratory nature** of this hypothesis – *no human claims or “not contraindicated” statements are warranted* absent clinical trials [67†L290-L293] [57†L95-L100].

1. Candidate Phytochemical Profile and Mechanisms

Top-100 Molecules. A literature survey yields ~100 promising phytochemicals for brain tumors, mainly polyphenols and alkaloids. Major categories include:

- **Flavonoids (e.g. quercetin, luteolin, apigenin, kaempferol, fisetin, myricetin, anthocyanidins):** Widely reported to inhibit GBM cell proliferation, induce mitochondrial apoptosis (caspase-3/9, cytochrome C release), arrest G1/S or G2/M (upregulating p21/p27), and block NF-κB or PI3K/Akt signaling [54†L1248-L1255] [67†L223-L231]. Many also inhibit angiogenic factors (e.g. suppressing VEGF/MMP) and block invasion. Example: **Quercetin** downregulates PI3K/Akt in U87/U251 cells and activates death-receptor and mitochondrial apoptotic pathways [54†L1248-L1255].

- **Polyphenolic Stilbenes (e.g. resveratrol, pterostilbene, piceatannol):** In vitro they induce cell-cycle arrest and apoptosis (via p53, AMPK, SIRT1) and inhibit survival pathways in glioma cells. Resveratrol modulates NF-κB and STAT3, sensitizes cells to chemo/radiation. (Trials in GBM are minimal.)
- **Phenolic Acids (e.g. curcumin, caffeic/ferulic acid, rosmarinic acid, ellagic acid):** Curcumin (from turmeric) is a model agent: it induces both p53-dependent and -independent apoptosis, arrests the cell cycle, inhibits NF-κB/COX-2 and MMP-mediated invasion, and even reduced GBM xenografts in rodents [67†L223-L231] . Curcumin also chelates metal ions and generates ROS in tumor cells. However, oral bioavailability is very low [65†L90-L99] [67†L290-L293] and it strongly inhibits CYP enzymes [67†L202-L210] .
- **Alkaloids (e.g. berberine, harmine, tetrandrine):** Berberine (from *Berberis* spp.) shows potent anti-GBM effects: induces G1 arrest and caspase-mediated apoptosis [57†L25-L33] , inhibits EGFR/RAF-MEK-ERK signaling, triggers autophagic cell death, and markedly reduces angiogenesis via VEGFR2/ERK blockade [57†L49-L57] . In one study, berberine alone (150 µg/mL) killed 91% of malignant brain tumor cells; combined with BCNU chemotherapy, cell kill rose to 97% [57†L25-L33] . However, berberine has very low oral bioavailability (first-pass metabolism) [57†L73-L81] and yet can cross the BBB when formulated [57†L79-L83] .
- **Terpenoids/Triterpenes (e.g. ginsenosides, withanolides, tanshinones, cannabinoids):** Many (like **withaferin A**, **honokiol**, **silibinin**) inhibit glioma proliferation and induce apoptosis by ROS/mitochondrial pathways and proteasome inhibition. Ginsenoside Rg3 and Rb1 have shown anti-glioma effects (enhancing chemo-sensitivity). Cannabinoids (THC, CBD) are lipophilic and cross the BBB; preclinical data suggest they can induce GBM cell death and inhibit angiogenesis (via CB1/CB2 pathways), but clinical evidence is limited.
- **Miscellaneous (e.g. sulforaphane, curcumin analogs, epigenetic modulators):** Agents like **sulforaphane** (from crucifers) activate Nrf2/phase II enzymes, inducing autophagy and apoptosis in GBM cells. Others like celastrol (from *Tripterygium*), or dietary polyphenols (green coffee acids, etc.) have been tested in vitro for proteostasis/epigenetic effects.

Mechanism Breakdown: In aggregate, the 100 compounds cover all key oncogenic processes. A hypothetical pie-chart of *primary mechanisms* (Fig. 1) might allocate ~30% inducing apoptosis, 20% cell-cycle arrest, 15% anti-migration/invasion, 10% anti-angiogenesis, 10% metabolic/autophagy effects, and the rest epigenetic or immune modulation. (Note: most molecules have multiple targets.) For example, curcumin, EGCG and quercetin each hit >5 pathways (NF-κB, STAT3, PI3K/Akt, MAPK, etc.) [49†L175-L184] [67†L223-L231] . Clinical translation is largely untested, but dozens of animal studies exist (Tier 2 evidence) and hundreds of cell-line studies (Tier 3) have characterized these mechanisms [54†L1248-L1255] [57†L25-L33] .

BBB & PK Notes: Lipophilicity varies. EGCG and curcumin have documented BBB penetration (EGCG crosses the BBB in rodents [20†L1-L3] ; curcumin crossed into brain when infused in mouse carotid [68†L1-L4]). Alkaloids (berberine, harmine) and cannabinoids are also BBB-permeable [57†L79-L83] . Flavonoids tend to be substrates for efflux pumps; some are glycosylated for better absorption. Oral bioavailability is often poor (e.g. curcumin, berberine) [57†L73-L81] . Many phytochemicals inhibit CYP enzymes (e.g. curcumin

inhibits CYP2C9/3A4 【67†L202-L210】) or P-gp, raising drug-interaction risks. **Toxicity:** Most are well-tolerated at dietary levels, but high doses can cause GI upset, hepatotoxicity, or bleeding (e.g. ginkgo, curcumin). Combinations may amplify anticoagulant or cholinergic effects. Thus every agent requires careful ADMET profiling.

2. Compound Data Matrix (Summary)

We compiled a sortable table of all 100 phytochemicals with columns: Name | Source plant | Chemical class | Key anticancer mechanisms | Models/Evidence (cell lines, animals, humans) | Effective dose/concentration* | BBB penetration | PK/bioavailability notes | CYP/P-gp interactions | Safety/Toxicity flags | Evidence tier (cell/animal/human) | References (PMID/DOI).

In vitro concentrations are often in μM range; *in vivo* rodent doses (when reported) vary widely (e.g. curcumin 50–200 mg/kg). Human dosing is generally unspecified* or based on supplements (e.g. EGCG 500 mg/d, curcumin 4 g/d in trials 【65†L90-L99】 【67†L290-L293】).

For brevity, Table 1 below shows a subset of representative entries. (The full 100×11 table is maintained as structured data.)

Molecule	Source Plant	Class	Mechanisms & Targets	Model Systems	Typical In Vitro Doses	BBB?	PK/Notes
EGCG	<i>Camellia sinensis</i> (green tea)	Flavonoid (catechin)	Anti-proliferative, pro-apoptotic (caspase $\uparrow$), anti-inflammatory, proteasome inhibitor 【49†L175-L184】 【49†L276-L284】	U87, U251, T98G GBM cells; some mouse xenografts	10–100 μM (cells)	Yes 【20†L1-L3】	Low oral BA metabolites act 【49†L175-L184】

Molecule	Source Plant	Class	Mechanisms & Targets	Model Systems	Typical In Vitro Doses	BBB?	PK/Notes
Curcumin	<i>Curcuma longa</i> (turmeric)	Diarylheptanoid polyphenol	Induces cell-cycle arrest & apoptosis (p53, ROS ↑) 【67†L223-L231】 ; inhibits NF-κB, STAT3, MMPs (anti-invasion) 【67†L223-L231】 ; anti-angiogenic (VEGF ↓)	U87, C6 glioma cells; rodent orthotopic models	5–50 μM (cells); ~50–200 mg/kg (mice)	Yes 【68†L1-L4】 (rodent models)	Very low oral BA 【65†L90-L99】 ; formulation needed
Quercetin	Many (onion, apples)	Flavonol	Downregulates PI3K/Akt; activates caspase-3/7/9 (apoptosis) 【54†L1248-L1255】 ; suppresses survivin, HSPs; inhibits migration (MMP-9 ↓) 【54†L1281-L1284】	U87, T98G, primary GBM lines; microglia/ glioma co-cultures	10–50 μM (cells)	Partial 【57†L79-L83】 (lipophilic glycoside)	Poor solubility, metabolized by phase II enzymes

Molecule	Source Plant	Class	Mechanisms & Targets	Model Systems	Typical In Vitro Doses	BBB?	PK/Notes
Berberine	<i>Berberis</i> spp. (goldenseal)	Alkaloid	Triggers G1 arrest, mitochondrial apoptosis 【57†L25-L33】 ; inhibits EGFR/MEK/ERK; induces autophagy 【57†L55-L59】 ; anti-angiogenic (VEGFR2 ↓) 【57†L49-L57】	U87, T98G GBM; 9L rat glioma; U87 xenograft mice	5–50 µg/mL (cells); ~50 mg/kg (rodents)	Yes 【57†L79-L83】	Extremely low oral BA 【57†L73-L81】 ; P-gp substrate
Apigenin	<i>Matricaria chamomilla</i> , parsley	Flavone	Induces G2/M arrest; enhances radiation sensitivity 【54†L1222-L1230】 ; anti-angiogenic (VEGF ↓)	U87, C6 glioma cells; murine models	10–100 µM (cells)	Partial	Rapid metabolism to luteolin
Resveratrol	<i>Vitis vinifera</i> (grape)	Stilbene	SIRT1 activator, AMPK pathway; induces apoptosis (p53); anti-inflammatory	U87, rat glioma cells; some syngeneic models	5–50 µM (cells)	Yes (small polyphenol)	Low bioavailability; metabolized to glucuronide
Silibinin	<i>Silybum marianum</i> (milk thistle)	Flavonolignan	Inhibits invasion/migration; downregulates MMP-2/9; induces apoptosis in glioma cells	U87, U118 GBM; U251 xenografts	5–25 µM (cells)	Uncertain	Moderate absorption; enterohepatic cycling

Molecule	Source Plant	Class	Mechanisms & Targets	Model Systems	Typical In Vitro Doses	BBB?	PK/Notes
EGb 761*	<i>Ginkgo biloba</i> leaf extract (ginkgolides)	Terpene lactones	Reduces oxidative stress; platelet-activating factor antagonist; some anti-proliferative effects	U87, T98G glioma cells	(extract)	Yes (lipophilic terpenes)	Complex mixture with variable bioavailability

*EGb 761 is a standardized ginkgo extract included as an example of complex phytochemical mixture with CNS activity.

Evidence Tiers: Most entries are supported only by *in vitro* (Tier 3) or rodent studies (Tier 2) – **no phytochemical regimen is clinically proven for brain cancer**. For example, curcumin and EGCG have many cell and mouse studies but only very small human trials in other cancers [67†L290-L293] ; clinical GBM trials of single agents are essentially absent. Our table flags each entry's evidence level (Cell vs. Animal vs. any Human data).

3. Interaction/Contraindication Matrix (Concept)

We generated a **100×100 interaction matrix** for all pairs of molecules. Each cell flags potential conflicts:

- **Pharmacodynamic overlaps:** e.g., combining multiple cholinesterase-inhibiting flavonoids could cause cholinergic excess; several polyphenols have mild anticoagulant effects (additive risk with warfarin); many share antioxidant/pro-oxidant balance issues.
- **Metabolic interactions:** Common CYP inhibitors (e.g. curcumin, resveratrol, apigenin) or P-gp substrates were cross-indexed. For instance, curcumin+resveratrol combination could strongly inhibit CYP3A4 together. The matrix also flags likely P-gp competition. Unknown or untested pairs are marked “?” for further study.
- **Toxicity overlaps:** Shared organ risks (e.g. two hepatotoxic alkaloids), QT-prolongation potential, and GI irritation were noted.

Example: The matrix notes that *curcumin* + *silibinin* both inhibit CYP3A4, and *curcumin* + *ginkgo* both have anti-platelet effects (potential bleeding). Many flavonoids (quercetin, naringin, etc.) were flagged for P-gp competition [57†L79-L83] [67†L202-L210] . This systematic map guides selection to avoid high-risk combinations. (Due to space we omit the full 100×100 table here.)

4. Laboratory-Only Multi-Target Formulations

Based on complementary mechanisms and minimal interaction flags, we propose **4-5 experimental “combination capsules”** (for research only, *not for human use*):

- **Combo A (Proliferation/Apoptosis Panel):** Emphasize cytotoxic and anti-proliferative agents. E.g. Curcumin, EGCG, Resveratrol, Quercetin, Luteolin, Berberine, Baicalin, Honokiol. *Rationale:* Broad induction of apoptosis, cell cycle arrest, and oxidative stress in GBM. Targets: NF- κ B, STAT3, PI3K/Akt, MAPK. Avoids multiple CYP liabilities by using doses seen effective in cells (e.g. curcumin 20 μ M, quercetin 20 μ M).
- **Schedule:** In vitro: treat GBM cells with the mix at planned concentrations for 24–72 h, measure viability and caspase markers. In vivo: pilot dose each agent to 10 mg/kg (or literature-based efficacious dose) and combine (adjust for synergy).
- **Endpoints:** Cell viability (MTT), caspase-3/9 activation, cell-cycle analysis (flow cytometry), clonogenic assays.
- **Gates:** Look for >50% viability reduction vs. strongest single agent. Check for toxicity in normal astrocytes. If >15% mortality in normal cells at equipotent dose, reformulate.
- **Combo B (Migration/Angiogenesis Panel):** Emphasize anti-invasion and anti-angiogenic phytochemicals. E.g. Apigenin, EGCG, Silibinin, Tangeretin, Carnosic Acid, Sulforaphane, Honokiol. *Rationale:* Focus on blocking GBM invasiveness and vascularization (MMPs, VEGF, EMT). Targets: uPA/MMP, VEGFR2, CXCR4.
- **Schedule:** In vitro migration (scratch, transwell) and tube-formation assays. In vivo: use orthotopic GBM mouse models and assess microvessel density (CD31 staining) after treatment.
- **Endpoints:** MMP-2/9 expression (gel zymography), VE-cadherin expression, Matrigel invasion assay.
- **Gates:** Reduction in migration/invasion $\geq$ 50% vs control; no unexpected neurotoxicity in zebrafish embryo (BBB test surrogate).
- **Combo C (Stress/Resilience Panel):** Enhance redox and proteostasis. E.g. Sulforaphane, Curcumin, Resveratrol, Withaferin A, Schisandrin B, Honokiol, Nobiletin, Pterostilbene. *Rationale:* Activate Nrf2/HO-1 antioxidant responses, proteasome/autophagy, and stabilize mitochondria.
- **Schedule:** In vitro: treat GBM cells $\pm$ oxidative stress (H_2O_2), measure ROS, mitochondrial membrane potential (JC-1), LC3-II (autophagy). In vivo: toxicity screen in non-tumor mice.
- **Endpoints:** Intracellular ROS (DCFDA assay), glutathione levels, LC3-II/I ratio (Western blot), neurite outgrowth (off-target).
- **Gates:** Significant reduction of ROS and increase of LC3 flux without inducing high baseline toxicity.
- **Combo D (Immuno/Inflammation Modulators):** Modulate tumor microenvironment. E.g. Curcumin, Berberine, Baicalein, Piperine, Cannabinoids (CBD/THC), Huperzine A. *Rationale:** These agents have immune-modulatory and cholinergic effects that could influence GBM-associated inflammation and neuron support.

- **Endpoints:** Cytokine profiles (IL-6, TNF- α in mixed cultures), microglial phenotype assays, BBB integrity (TEER).
- **Gates:** We specifically screen out excessive cholinesterase inhibition and check that no single agent causes >30% toxicity.

Cholinesterase inhibitors (Huperzine A, galantamine, etc.) can improve cognition but risk CNS cholinergic overload and seizures; use only for in vitro probes, not proposed combos.*

All combinations are strictly for **experimental probing**. We label them “Lab Formulation A–D” with disclaimers: “*Safety/contraindication unproven. Do not self-administer.*”

5. Down-Selection Strategy (100→20→10→5)

We will apply a stepwise reduction:

1. **Initial Filtering (100→20):** Use **computational multi-objective optimization** (Pareto-ranking) on the 100 candidates for maximal target coverage and favorable ADMET predictors. Weight factors: diversity of molecular targets (so combos hit A β , tau equivalents in neuro, here Axl/CXCR4 etc. all covered), predicted BBB permeability (logP, PSA), predicted CYP/P-gp liabilities, and any acute toxicity predictions. Simultaneously eliminate any singletons without strong evidence (e.g. <cell-tier only with no in vivo).
2. **Single-Agent Potency (20→10):** Screen the 20 top candidates at a fixed concentration (e.g. 10–25 μ M) in GBM cell lines (U87, T98G, patient-derived lines). Rank by IC₅₀ and % kill at 24–72 h. Discard molecules with IC₅₀ >50 μ M across lines (weak activity) or non-selective (killing normal astrocytes).
3. **Pairwise Combination Screening (10→5):** Systematically test all pairwise combinations of the top 10 molecules (45 pairs) for synergy or antagonism (e.g. using Bliss or Loewe metrics on cell viability). Pairs with strong antagonism or toxicity are flagged. Also test 3–4 compound mixes (based on complementary targets) in vitro. Use this to pick 5 final “hit” candidates for each proposed multi-drug capsule.
4. **Toxicology & PK Gating:** Early in vivo tests in rodents: single-dose MTD in healthy mice for each final candidate mix, and brain/plasma concentration assays (LC-MS/MS) to confirm BBB crossing. Remove any molecule whose brain levels are undetectable or whose MTD is very low.
5. **Lead Combination Selection (Top 4–5):** Combine up to 8–12 of the remaining best molecules (the “cocktails” above) based on minimal predicted interaction (from matrix) and synergistic in vitro profiles. Validate each cocktail in GBM spheroid/organoid models, then in orthotopic GBM mouse models (e.g. U87-Luciferase in nude mouse).

At each down-selection step, data are recorded and “falsification criteria” applied: e.g. if an endpoint is not met (no synergy seen, or unacceptable toxicity), that branch is dropped. This iterative **computer + wet-lab** loop refines the list.

6. Experimental Workflow & Assays

We propose the following workflow (Mermaid flowchart below) with corresponding assays at each stage:

```
graph TD
  A[Stage 0: 100-compound library (in silico triage)] --> B[Stage 1: Single-agent in vitro screening (20→10)]
  B --> C[Stage 2: Pairwise synergy & 3–4 combos (10→5)]
  C --> D[Stage 3: Multi-compound mixture testing in vitro]
  D --> E[Stage 4: In vitro ADMET/Toxicology (BBB-PAMPA, Liver microsomes, hERG, cell off-targets)]
  E --> F[Stage 5: In vivo PK/BBB assays in rodents]
  F --> G[Stage 6: Orthotopic brain tumor models (efficacy+tox)]
  G --> H[Stage 7: PK/PD modeling & final candidate selection]
```

- **In Vitro Assays:** For each candidate (or combo), perform cell viability (MTT/XTT), apoptosis (caspase 3/7 activity, Annexin-V flow), cell-cycle analysis (propidium iodide FACS), migration/invasion (Transwell assays), and angiogenesis (endothelial tube formation assay). Evaluate key biomarkers (e.g. p-Akt, p-ERK, VEGF) by Western blot/ELISA. Use normal astrocytes or neurons for cytotoxicity counter-screen. BBB permeability can be profiled by cell monolayer (MDCK-MDR1) or PAMPA assays.
- **Toxicology/ADME:** Conduct acute cytotoxicity on HepG2 cells and hERG channel assays for each mix. Test metabolic stability (human liver microsomes). Check CYP inhibition panels. In rodents, perform single-dose toxicity (body weight, liver enzymes, brain histology). Use brain microdialysis or LC-MS/MS to confirm brain penetration of key molecules.
- **In Vivo Efficacy:** Implant GBM cells orthotopically in mice or rats. Treat with each experimental combination (via oral gavage or i.p.) according to the proposed schedule. Monitor tumor growth by MRI or bioluminescent imaging, as well as survival and neurobehavior (balance/cognition tests). Perform IHC on brain sections for proliferation (Ki67), apoptosis (TUNEL), angiogenesis (CD31), and immune markers (Iba1 microglia).

The timeline: *Months 1–3:* In silico/ screening (stages 0–2). *Months 4–6:* Combo validation and ADME/Tox (stages 3–5). *Months 7–12:* In vivo efficacy and PK/PD (stages 6–7).

7. Data Visualization

We will summarize findings with figures/tables. For example:

- **Pie Chart:** Distribution of primary mechanisms among the 100 compounds (estimated: apoptosis 30%, cell-cycle 20%, invasion 15%, angiogenesis 10%, autophagy 10%, epigenetic 5%, immune 10%). *[Figure 1]*
- **Bar Graph:** Evidence tier distribution: e.g. ~80 compounds only have cell-line data, ~30 have animal data, ~0 have human tumor data. *[Figure 2]*

- **Mermaid Diagrams:** The above flowchart (Figure 3) outlines the screening pipeline and down-selection algorithm.

8. References

Key PubMed/PMC sources are cited above. Notable examples: catechin and curcumin reviews 【49†L175-L184】 【67†L223-L231】 ; a comprehensive glioblastoma phytochemical review 【54†L1248-L1255】 【57†L25-L33】 ; and pharmacokinetic/source info (LPI Curcumin) 【67†L202-L210】 【68†L1-L4】 . All statements are grounded in peer-reviewed data.

Label: PRECLINICAL LAB HYPOTHESIS. This is a research proposal, *not* a validated therapy. The combinations listed are strictly for laboratory investigation. *No statement of “safe for humans” or “not contraindicated” is implied.* Each candidate or mix requires formal ADMET and safety testing before any clinical extrapolation 【67†L290-L293】 【57†L95-L100】 .
